611 XTX202–01/02–001, Phase 1/2 first-in human study of XTX202, a masked, tumor-activated IL-2βγ, in patients with advanced solid tumors: results from phase 1 oleh David Miller, John Powderly, Suthee Rapisuwon, Sanjay Goel, Bartosz Chmielowski, Richard Wu, Meredith McKean, Damiano Fantini, Yousef Zakharia, Jacob Thomas, Diana Hanna, Anthony El-Khoueiry, Ekta Patel, Anurag Gupta, George Lee, Meghan Duncan, Meredith Pelster, Randy Hurley, Aika Siu, David Crowe, Sattanathan Paramasivan, Katarina Luptakova